This phase 1 study is to determine the optimal dose and tolerability of a hypoxia-activating agent, tirapazamine, when it is combined with embolization in live…

Hepatocellular CarcinomaGastrointestinal Cancer MetastaticNeuroendocrine Tumors

~Estimated

~$10 – $8,750

Teclison Ltd.NCT02174549

Phase 1

Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy

This is a Phase I study to evaluate the safety and tolerability of sacituzumab govitecan in combination with capecitabine for advanced gastrointestinal cancers…

Gastrointestinal Cancer

~Estimated

~$10 – $6,250

Henry Ford Health SystemNCT06065371

← PreviousPage 4 of 4Next →